reMYND

reMYND is a private, clinical-stage biotech developing novel oral therapeutics targeting synaptic and neuronal dysfunction in Alzheimer's and Huntington's disease. Its lead asset, REM392, is an oral small molecule designed to restore calcium homeostasis to provide both symptomatic and disease-modifying benefits in Alzheimer's. The company leverages a dual-strategy business model, combining internal drug development with a revenue-generating CRO service that validates its scientific platform and funds R&D.

Platform focused on developing oral small molecules that restore neuronal calcium (Ca²⁺) homeostasis to rescue synaptic dysfunction and reduce pathology in neurodegenerative diseases. Validated through proprietary in-vivo mouse models used in its CRO services.

In Alzheimer's, reMYND competes with large pharma (Biogen/Eisai, Lilly) with approved amyloid antibodies and a crowded pipeline of other modalities. Its oral, small molecule approach targeting synaptic function is a key differentiator. In Huntington's and ALS, it faces both large and small biotechs exploring genetic and non-genetic mechanisms.